OnPoint Analytics is an economic, finance and statistical consultancy specializing in expert testimony for complex, high-stakes litigation. The firm has been involved in many of the largest cases of the last decade in numerous areas, including antitrust, intellectual property, class certifications, pharmaceuticals and environmental damages. Our experts include first rate economists and statisticians, and we have a highly skilled staff of economists, statisticians, database architects and document analysts dedicated to providing clients with tailored, empirically focused work product, accessible to the lay audience.

OnPoint Experts Address Evolving Class Certification Standards in Antitrust Magazine
April 20, 2016 – OnPoint experts Gordon Rausser and Gareth Macartney co-authored an article featured in the Spring 2016 issue of Antitrust Magazine—an issue entirely devoted to class actions on the 50th anniversary of the 1966 amendments to Rule 23 of the Federal Rules of Civil Procedure, which governs class action cases in federal courts. The article explores how certification standards have become increasingly rigorous in class action litigation, particularly with recent landmark rulings in In re Hydrogen Peroxide Antitrust Litigation (2008), Wal-Mart Stores, Inc. v. Dukes (2011), and Comcast Corp. v. Behrend (2013). Click here to learn more.

Pharma Corner blue

Biologics Exclusivity and the TPP: An International Balancing Act
October 6, 2015—With sufficient participation, trade pacts have the potential to set international standards that eventually become global norms. This is exactly what opponents on both sides of the Trans-Pacific Partnership (TPP) agreement fear will happen when it comes to biosimilar drug development. The deal, announced October 5, 2015, would apparently commit the 12 participant nations to guarantee at least 5 years of data exclusivity for biologic drugs, thereby assuring them immunity from biosimilar competition for at least that period, regardless of the existence of any patent protection. Some reports have suggested that there may be an additional 3 years of exclusivity tacked on in the form of a “safety monitoring period” that would precede commercial sales, and possibly even regulatory review, of the proposed biosimilar. Click here to learn more.